Reducing the incidence of daily life pain in patients with sickle cell disease - NAC Trial

Academisch Medisch Centrum0 个研究点目标入组 65 人开始时间: 待定最近更新: 2024年4月29日

试验速览

暂无简介。

•- Age 12 years or older
•- Either HbSS, HbSC, HbS*0- or HbS*+-thalassemia genotype
•- History of at least 1.0 painful crisis per year in the past 3 years (hospital admission is not obligatory here).
•- Written informed consent from patient/parent/guardian

•- Chronic blood transfusion or transfusion in the preceding 3 months
•- Painful crisis in the last 4 weeks (hospital admission is not obligatory here)
•- Pregnancy, breastfeeding or the desire to get pregnant in the following 9 months
•- Known active gastric/duodenal ulcers
•- Hydroxycarbamide (HC) treatment with unstable dose in the last 3 months or
•started on HC shorter then 6 months prior to study.
•- Known poor compliance in earlier trials regarding the completion of pain diaries.
•- Insufficient compliance in run-in period.
•- - Known of hypersensitivity to acetylcysteine or one of the other components of the study
•-Use of pain medication for sickle-cell related pains on more than 15 days per month in the past 6 months (*chronic pain*).

发起方